In addition to providing information on tumor aggressiveness, this measurement of RAC1 activity could be used as a predictive tumor biomarker to select patients whose tumors are characterized by high RAC1 activation and for whom the therapeutic use of an inhibitor of RAC1 activity would be beneficial. Here, RAC1 is linked to neoplasm.